Two type Ib MET-tyrosine kinase inhibitors (TKIs), capmatinib and tepotinib, were recently approved for the treatment of non-small-cell lung cancer (NSCLC) patients carrying MET exon 14 skipping mutations (METex14). The gene discussed is MET; the disease is non-small cell lung carcinoma.